Fibrin/Fibrinogen Degradation Product Kit
Nanopia P-FDP
We created this page for medical staff.
- *Read carefully the package insert before use.
Reference Data
Within-run reproducibility
| Sample 1 | Sample 2 | |
|---|---|---|
| 1 | 3.5 | 9.5 |
| 2 | 3.6 | 9.5 |
| 3 | 3.5 | 9.4 |
| 4 | 3.4 | 9.3 |
| 5 | 3.5 | 9.5 |
| 6 | 3.5 | 9.3 |
| 7 | 3.5 | 9.4 |
| 8 | 3.6 | 9.5 |
| 9 | 3.5 | 9.5 |
| 10 | 3.5 | 9.3 |
| Mean | 3.5 | 9.4 |
| S.D. | 0.06 | 0.09 |
| C.V. (%) | 1.6 | 1.0 |
| Max. | 3.6 | 9.5 |
| Min. | 3.4 | 9.3 |
| Range | 0.2 | 0.2 |
On-Board Stability (After Reconstitution)
[on Coapresta 2000]
Interference
| Concentration | Measured Value(µg/mL) | ||
|---|---|---|---|
| Base Plasma | Spiked Plasma | ||
| Unconjugated Bilirubin | 20 mg/dL | 2.70 | 2.80 |
| Conjugated Bilirubin | 20 mg/dL | 2.80 | 2.80 |
| Hemoglobin | 500 mg/dL | 2.12 | 2.14 |
| Chyle | 2500 FTU | 2.17 | 2.04 |
Linearity
Correlation
Assay Procedure on Coapresta 2000
"Nanopia" is a trademark or registered trademark of SEKISUI MEDICAL CO., LTD. in Japan and/or other countries.
We prepared this page for medical staff (doctors, dentists, pharmacists, clinical laboratory technicians, nurses, etc.) in Japan to ensure the correct use of our products. You should be aware that the information provided is not intended for overseas medical staff and the general public.